Please login to the form below
Storm Therapeutics
This page shows the latest Storm Therapeutics news and features for those working in and with pharma, biotech and healthcare.
RNA-focused biotech Storm Therapeutics raises extra £14m
New head of translational oncology also hired. Storm Therapeutics, the UK-based biotech specialising in modulating RNA modifying enzymes has announced that it has raised an extra £14m ($17.8m) from ... Keith Blundy. Dr Keith Blundy, chief executive of
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Latest appointments
-
Professor Thomas Cech joins Storm Therapeutics
He takes up a scientific advisor role at the group. Storm Therapeutics, a company focused on the discovery of small molecule therapies has appointed Professor Thomas Cech as its scientific advisor. ... Commenting on the new appointments, Keith Blundy,
-
Storm Therapeutics bolsters its team
UK-based drug discovery group Storm Therapeutics has strengthened its scientific advisory board with the addition of Professor Mark Dawson. ... Keith Blundy, chief executive officer of Storm Therapeutics, said: “Mark’s expertise in epigenetics
-
Storm Therapeutics strengthens its board
Professor Paul Workman joins as an independent director. Drug discovery group Storm Therapeutics has appointed Professor Paul Workman to join its board. ... UK. Keith Blundy, CEO, Storm Therapeutics, said: “I am pleased to welcome Paul as indepdent
More from appointments
Approximately 3 fully matching, plus 0 partially matching documents found.
Featured jobs
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
- FREELANCE Account Director – Healthcare Advertising – London – 3...
-
Competitive Daily Rates
- Account Director, Healthcare Communications
-
Salary TBC
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
-
Account Director – UK Office
-
Excellent salary and benefits
Subscribe to our email news alerts
- Finch Therapeutics bags $53m for microbiome therapies
- MSD taps Austria’s Themis to bolster vaccine pipeline
- Early ‘no’ for GW Pharma’s epilepsy drug, but NICE vows to collaborate
- GSK preps filings for BCMA-targeting multiple myeloma drug
- Behaviour change – is there something missing?
- NICE’s long-serving chief exec Sir Andrew Dillon to step down
PMHub
VCCP Health
We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...
Latest intelligence
- Empowered patients: shaking the foundations of healthcare
- Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
- A uniquely English genomic medicine service
- The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
- Blended Intelligence
- Data is the most valued commodity of the modern world. For P&P it's all about the application....
Quick links
Infographics
